Porcine Immunoglobulin Fc Fused P30/P54 Protein of African Swine Fever Virus Displaying on Surface of S. cerevisiae Elicit Strong Antibody Production in Swine

African swine fever virus (ASFV) infects domestic pigs and European wild boars with strong, hemorrhagic and high mortality. The primary cellular targets of ASFV is the porcine macrophages. Up to now, no commercial vaccine or effective treatment available to control the disease. In this study, three recombinantSaccharomyces cerevisiae(S. cerevisiae) strains expressing fused ASFV proteins-porcine Ig heavy chains were constructed and the immunogenicity of theS. cerevisiae-vectored cocktail ASFV feeding vaccine was further evaluated. To be specific, the P30-Fc gamma and P54-Fc alpha fusion proteins displaying on surface ofS. cerevisiaecells were produced by fusing the Fc fragment of porcine immunoglobulin IgG1 or IgA1 withp30orp54gene of ASFV respectively. The recombinant P30-Fc gamma and P54-Fc alpha fusion proteins expressed byS. cerevisiaewere verified by Western blotting, flow cytometry and immunofluorescence assay. Porcine immunoglobulin Fc fragment fused P30/P54 proteins elicited P30/P54-specific antibody production and induced higher mucosal immunity in swine. The absorption and phagocytosis of recombinantS. cerevisiaestrains in IPEC-J2 cells or porcine alveolar macrophage (PAM) cells were significantly enhanced, too. Here, we introduce a kind of cheap and safe oralS. cerevisiae-vectored vaccine, which could activate the specific mucosal immunity for controlling ASFV infection.

Automated summary

A recombinant Saccharomyces cerevisiae (S. cerevisiae) vaccine was constructed to control African swine fever virus (ASFV) infection, which induced specific antibody production in pigs, enhanced mucosal immunity, and improved cell adhesion and phagocytosis capabilities.